Delivery Order SPE2DB25D3306-SPE2DB25FUCYF
- Not listed
- The Defense Logistics Agency awarded a $4,030.39 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This is a firm fixed price, competitively awarded contract with a completion date of September 29, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation, indicating it was awarded through...
- The Defense Logistics Agency awarded a $15,944.25 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $7,848.75 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 21, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single transaction under the company's larger pharmaceutical supply framework with the federal...
- The Defense Logistics Agency awarded a $3,666.44 delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This competitively awarded, firm fixed price contract is classified as a delivery order with an ultimate completion date of August 22, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order...
- The Defense Logistics Agency awarded a $43,449.54 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pen injectors on September 24, 2025, with a completion date of September 25, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a single-transaction purchase under the company's broader relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $2,110.44 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors on May 30, 2025, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price delivery order utilizes no set-aside designation and specifies performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction within...
- The Defense Logistics Agency awarded a $10,285.92 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This is a firm fixed price, competitively awarded contract with a completion date of August 15, 2025, and performance to be executed at the contractor's Conshohocken, Pennsylvania facility. The delivery order represents a child contract issued under AmerisourceBergen's broader relationship with the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $4,411.39 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 14, 2025, with a completion date of August 15, 2025. This firm fixed-price delivery order represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 19, 2025. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a small transaction within the...
- The Defense Logistics Agency awarded a $1,743.48 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injectors. The contract is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 29, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCYFDelivery Order
The Defense Logistics Agency awarded a $4,839.72 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is expected to be completed by September 15, 2025, and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of brand-name and generic medications, vaccines, and medical devices to support military and veteran healthcare systems. The company's extensive portfolio of federal contracts demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency and other federal health systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 9/12/25 |